| 词条 | Voxilaprevir |
| 释义 |
| drug_name = | type = | IUPAC_name = (1R,18R,20R,24S,27S,28S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide | image = Voxilaprevir.svg | alt = | caption = | pronounce = | tradename = Vosevi (combination with sofosbuvir and velpatasvir) | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category = | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1535212-07-7 | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 89921642 | DrugBank = | ChemSpiderID = 44209500 | UNII = 0570F37359 | KEGG = D10899 | chemical_formula = | C = 40 | H = 52 | F = 4 | N = 6 | O = 9 | S = 1 | molecular_weight = | smiles = CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C | StdInChI = 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 | StdInChIKey = MZBLZLWXUBZHSL-FZNJKFJKSA-N | density = 1.4±0.1[1] }}Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[2] On 18 July 2017, Vosevi was approved by Food and drug administration.[3] References1. ^{{Cite web|url=https://www.chemsrc.com/en/cas/1535212-07-7_1287459.html|title=voxilaprevir_msds}} {{RNA antivirals}}{{antiinfective-drug-stub}}2. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=European Medicines Agency|title=Summary of opinion: Vosevi|date=22 June 2017}} 3. ^[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm FDA approves Vosevi for Hepatitis C ] 2 : NS3/4A protease inhibitors|Tert-butyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。